iBio reported preclinical results for antibody candidate IBIO-610: a single dose reduced active Activin E levels by up to 98% in obese non-human primates, with suppression lasting through 8 weeks. The magnitude and durability of the biomarker knockdown are supportive for the candidate’s potential efficacy. While still preclinical, the data are likely to be viewed positively for the program’s near-term investor outlook.
iBio reported preclinical results for antibody candidate IBIO-610: a single dose reduced active Activin E levels by up to 98% in obese non-human primates, with suppression lasting through 8 weeks. The magnitude and durability of the biomarker knockdown are supportive for the candidate’s potential efficacy. While still preclinical, the data are likely to be viewed positively for the program’s near-term investor outlook.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
